{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:28:10Z","timestamp":1785644890515,"version":"3.56.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study evaluated anti-modified citrullinated vimentin (anti-MCV) performance in determining the clinical picture and outcomes of palindromic rheumatism (PR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a retrospective study, patients with PR with at least 1 year of follow-up diagnosed according to clinical criteria were enrolled. Anti-MCV antibodies were measured, and levels &amp;gt;20 IU\/mL were considered positive. Disease prognosis was assessed according to patients acquiring remission and preventing PR from developing into rheumatoid arthritis (RA) or other diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-six patients with PR with a mean follow-up of 30.57 months (median = 21 months; minimum = 12 months; maximum = 48 months) were included in the study. Anti-MCV antibodies were positive in 69.7% of patients. Metacarpophalangeal (MCP) joint involvement and positive anti-cyclic citrullinated peptides were significantly higher in patients who were anti-MCV-positive, whereas ankle joint involvement was significantly lower. No significant correlation was observed between the anti-MCV titer and the severity of attacks. Remission in patients who were anti-MCV-positive and negative was 75.5% and 78.3%, respectively, with no significant difference. Evolution to RA was observed in only 3.8% of patients who were anti-MCV-positive. No patients who were anti-MCV-negative developed RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Except for MCP and ankle joint involvement, anti-MCV was not helpful in determining the clinical picture and outcome of PR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmaa095","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T11:08:53Z","timestamp":1601636933000},"page":"357-363","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Significance of Anti-Modified Citrullinated Vimentin Antibodies in Palindromic Rheumatism"],"prefix":"10.1093","volume":"52","author":[{"given":"Aida","family":"Malek Mahdavi","sequence":"first","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadereh","family":"Rashtchizadeh","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsanam","family":"Khaknejad","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Sakhinia","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Division of Regenerative Medicine, School of Medicine, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-6967","authenticated-orcid":false,"given":"Alireza","family":"Khabbazi","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sousan","family":"Kolahi","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"4","key":"2021070116493985500_CIT0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1756-185X.2012.01739.x","article-title":"A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran","volume":"15","author":"Khabbazi","year":"2012","journal-title":"Int J Rheum Dis."},{"issue":"5","key":"2021070116493985500_CIT0002","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.berh.2004.05.005","article-title":"Palindromic rheumatism and other relapsing arthritis","volume":"18","author":"Sanmarti","year":"2004","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"5","key":"2021070116493985500_CIT0003","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2217\/ijr.13.51","article-title":"Palindromic rheumatism: a reappraisal","volume":"8","author":"Cabrera-Villalba","year":"2013","journal-title":"Int J Clin Rheumatol"},{"issue":"8","key":"2021070116493985500_CIT0004","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00296-019-04325-5","article-title":"Rheumatology training and research in Iran","volume":"39","author":"Khabbazi","year":"2019","journal-title":"Rheumatol Int."},{"key":"2021070116493985500_CIT0005","article-title":"Is palindromic rheumatism a pre-rheumatoid arthritis condition? Low incidence of rheumatoid arthritis in palindromic rheumatism patients treated with tight control strategy","author":"Khabbazi","year":"2019","journal-title":"Reumatol Clin"},{"issue":"11","key":"2021070116493985500_CIT0006","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41584-019-0308-5","article-title":"Palindromic rheumatism as part of the rheumatoid arthritis continuum","volume":"15","author":"Mankia","year":"2019","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"2021070116493985500_CIT0007","first-page":"540","article-title":"Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism","volume":"26","author":"Gonzalez-Lopez","year":"1999","journal-title":"J Rheumatol."},{"issue":"12","key":"2021070116493985500_CIT0008","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2169\/internalmedicine.45.1407","article-title":"Examination of IgM rheumatoid factor (IgM-RF) and anti-cyclic citrullinated peptide antibody (anti-CCP Ab) in Japanese patients with palindromic rheumatism","volume":"45","author":"Tamai","year":"2006","journal-title":"Intern Med."},{"issue":"4","key":"2021070116493985500_CIT0009","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/03009741003604534","article-title":"Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism","volume":"39","author":"Tamai","year":"2010","journal-title":"Scand J Rheumatol."},{"issue":"2","key":"2021070116493985500_CIT0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5114\/aoms.2011.22067","article-title":"Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis","volume":"7","author":"Puszczewicz","year":"2011","journal-title":"Arch Med Sci."},{"issue":"3","key":"2021070116493985500_CIT0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","article-title":"Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"8","key":"2021070116493985500_CIT0012","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.22817","article-title":"Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis","volume":"56","author":"Bang","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2021070116493985500_CIT0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ncb898","article-title":"Vimentin is secreted by activated macrophages","volume":"5","author":"Mor-Vaknin","year":"2003","journal-title":"Nat Cell Biol."},{"issue":"8","key":"2021070116493985500_CIT0014","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/art.24716","article-title":"Value of anti\u2013modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis","volume":"60","author":"van der Linden","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2021070116493985500_CIT0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/ard.2008.103283","article-title":"Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review","volume":"69","author":"Luime","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"2021070116493985500_CIT0016","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/keg268","article-title":"Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?","volume":"42","author":"Salvador","year":"2003","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"2021070116493985500_CIT0017","first-page":"1240","article-title":"The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis","volume":"33","author":"Russell","year":"2006","journal-title":"J Rheumatol."},{"issue":"9","key":"2021070116493985500_CIT0018","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.7863\/jum.2009.28.9.1193","article-title":"Association of ultrasonographic findings of synovitis with anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with palindromic rheumatism during active episodes","volume":"28","author":"Chen","year":"2009","journal-title":"J Ultrasound Med."},{"issue":"6","key":"2021070116493985500_CIT0019","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10067-014-2569-3","article-title":"In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up","volume":"33","author":"Emad","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2021070116493985500_CIT0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-017-1329-6","article-title":"Differing specificities and isotypes of anticitrullinated peptide\/protein antibodies in palindromic rheumatism and rheumatoid arthritis","volume":"19","author":"Cabrera-Villalba","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2021070116493985500_CIT0021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0002-9343(92)90177-D","article-title":"Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis","volume":"93","author":"Guerne","year":"1992","journal-title":"Am J Med."},{"issue":"10","key":"2021070116493985500_CIT0022","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3899\/jrheum.120568","article-title":"Palindromic rheumatism with positive","volume":"39","author":"Sanmart\u00ed","year":"2012","journal-title":"J Rheumatol"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/4\/357\/38848297\/lmaa095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/4\/357\/38848297\/lmaa095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:38:38Z","timestamp":1625161118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/52\/4\/357\/6025078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaa095","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,7]]}}}